Curcumin - Levolta Pharmaceuticals

Drug Profile

Curcumin - Levolta Pharmaceuticals

Alternative Names: VOLT-03; VOLT-3

Latest Information Update: 26 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Levolta Pharmaceuticals
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; Immunosuppressants; Mast cell stabilisers; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer; Inflammation

Most Recent Events

  • 26 May 2016 Chemical information added
  • 24 May 2016 Phase I development is ongoing in USA
  • 03 Nov 2014 Phase-I clinical trials in Cancer in USA prior to this date (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top